LIPOFLAVON® APPLICATION FOR PHARMACOLOGICAL CORRECTION OF ENDOTHELIAL DYSFUNCTION IN DIABETIC RATS
DOI: http://dx.doi.org/10.30970/sbi.0703.306
Abstract
It is known that endothelial dysfunction is one of the major factors in development of diabetic cardio-vascular complications. Besides, pathophysiological linkages between high concentration of glucose and vascular dysfunction remain not fully established. The aim of this study was to investigate acetylcholine-induced endothelium-dependent dilation of vascular segments obtained from healthy rats and incubated in hyperglycemic solution and vascular segments from diabetic rats before and after quercetin-filled phosphatidylcholine liposomes (Lipoflavon®) treatment in both in vitro and in vivo conditions. Changes in vascular tone were registered in isometric mode. Data are presented as mean ± SEM with “n” indicating the number of vascular preparations tested. On the day of the experiment diabetic rats showed four times higher blood glucose level and decreased dilation responses to acetylcholine (ACh, 1 nM–10 mM) of aortic rings precontracted with noradrenaline (NA, 1 mM)as compared to controls. Incubation of vascular rings under hyperglycemic (25 mM/L glucose) conditions led to time-dependent impairment of dilation responses as compared to normoglycemic (5.5 mM/L glucose) conditions. Lipoflavon® (3 µg/mL of quercetin) application to the organ bath with diabetic rats precontracted vascular rings resulted in a significant reduction in vascular tension. Being added on the plateau of Lipoflavon® relaxation, ACh showed increased dilation responses in comparison to diabetic tissues without Lipoflavon® application. Intravenous Lipoflavon® injections to diabetic rats in concentrations 15 mg/kg or 50 mg/kg of phosphatidylcholine restored dilatation responses up to the control level. In conclusion, we confirmed that hyperglycemia is one of the main factors leading to impairment of endothelium-dependent vasodilation. Quercetin-filled phosphatidylcholine liposomes significantly improve endothelium-dependent relaxation of isolated vascular rings from diabetic rats. We assume that Lipoflavon® is perspective in treatment of diabetic angiopathies.
Keywords
Full Text:
PDF (Українська)References
1. Клименко К.І. Новохацька Т.В., Кізуб І.В., Соловйов А.І. Вплив Ліпофлавону на сумарні вихідні K+-струми в гладеньком'язових клітинах аорти щурів із цукровим діабетом. Фармакологія та лікарська токсикологія, 2012; 5(30): 31-36. | |
| |
2. Соловьев А.И., Стефанов А.В. Фармакология и токсикология оксида азота: два "лица" одной и той же молекулы. Современные проблемы токсикологии, 1998; 1: 35-38. | |
| |
3. Хромов О.С., Добреля Н.В. Експериментальне обґрунтування застосування фосфатидилхолінових ліпосом як нового гіпотензивного засобу. Вісник Дніпропетр. ун-ту. Біологія. Екологія, 2008; 1 (16):197-203. | |
| |
4. Annapurna A., Reddy C.S., Akondi R.B., Rao S.R. Cardioprotective actions of two bioflavonoids, quercetin and rutin, in experimental myocardial infarction in both normal and streptozotocin-induced type I diabetic rats. J. Pharm. Pharmacol, 2009; 61(10): 1365-74. | |
| |
5. Avogaro A., Albiero M., Menegazzo L. et al. Endothelial dysfunction in diabetes. The role of reparatory mechanisms. Diabetes Care, 2011; 34 (2): S285-S290. | |
| |
6. Bayraktutan U. Free radicals, diabetes and endothelial dysfunction. Diabetes, Obesity and Metabolism, 2002; 4(4): 224-238. | |
| |
7. Bohlen H.G., Lash J.M. Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat arterioles. Am. J. Physiol, 1993; 265: H219-H225. | |
| |
8. Calles-Escandon J., Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocrine Reviews, 2001; 22: 36-52. | |
| |
9. Cogolludo A., Frazziano G., Briones A.M. The dietary flavonoid quercetin activates BKCa currents in coronary arteries via production of H2O2. Role in vasodilatation. Cardiovascular Research, 2007; 73: 424-431. | |
| |
10. Cosentino F., Hishikawa K., Katusic Z.S., Lüscher T.F. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells, Circulation, 1997; 96: 25-28. | |
| |
11. De Vriese A.S., Verbeuren T.J., Van de Voorde J. et al. Endothelial dysfunction in diabetes. Br. J. Pharmacol, 2000; 130: 963-974. | |
| |
12. Dorigo P., Fraccarollo D., Santostasi G., Maragno I. Impairment of endothelium-dependent but not of endothelium-independent dilatation in guinea-pig aorta rings incubated in the presence of elevated glucose, Br. J. Pharmacol, 1997; 121: 972-976. | |
| |
13. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev, 2002; 23: 599-622. | |
| |
14. Geng Y., Xue L., Liu C., Gu Y. Effect of liposomal quercertin on advanced glycation end products and receptor for advanced glycation end products in retina of diabetic rats. Chin. J. Clinicians (Electronic Edition), 2010; 4(12). | |
| |
15. Geraldes P., King G.L. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ. Res, 2010; 106: 1319-1331. | |
| |
16. Goel A., Zhang Y., Anderson L., Rahimian R. Gender difference in rat aorta vasodilation after acute exposure to high glucose: Involvement of protein kinase C β and superoxide but not of Rho Kinase. Cardiovascular Research, 2007; 76: 351-360. | |
| |
17. Han G., Yu X., Lu L. et al. Estrogen receptor alpha mediates acute potassium channel stimulation in human coronary artery smooth muscle cells. J. Pharmacol. Exp. Ther, 2006; 316(3): 1025-30. | |
| |
18. Ishii H., Jirousek M.R., Koya D. et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science, 1996; 272:728-731. | |
| |
19. Kakimoto M., Inoguchi T., Sonta T. et al. Accumulation of 8-hydroxy-2′-deoxyguanosine and mitochondrial DNA deletion in kidney of diabetic rats. Diabetes, 2002; 51:1588-1595. | |
| |
20. Keenan H.A., Costacou T., Sun J.K. et al. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care, 2007; 30: 1995-1997. | |
| |
21. Kelly G.S. Quercetin. Monograph. Altern. Med. Rev, 2011; 16(2): 172-94. | |
| |
22. Kyaw M., Yoshizumi M., Tsuchiya K. et al. Atheroprotective effects of antioxidants through inhibition of mitogen-activated protein kinases. Acta Pharmacol. Sin, 2004; 25 (8): 977-985. | |
| |
23. Lakhanpal P., Rai D.K. Role of quercetin in cardiovascular diseases. Internet J. of Med. Update, 2008; 3(1): 31-49. | |
| |
24. Leo C.H., Hart J.L., Woodman O.L. Impairment of both nitric oxide-mediated and EDHF-type relaxation in small mesenteric arteries from rats with streptozotocin-induced diabetes. Br. J. Pharmacol, 2011; 162(2): 365-377. | |
| |
25. Liu Y., Terata K., Rusch N.J., Gutterman D.D. High Glucose impairs voltage-gated K+ channel current in rat small coronary arteries. Circ. Res, 2001; 89: 146-152. | |
| |
26. Lu T., Zhang D.M., Wang X.L. et al. Regulation of coronary arterial BK channels by caveolae-mediated angiotensin II signaling in diabetes mellitus Circ. Res, 2010; 106(6): 1164-1173. | |
| |
27. Lyle A.N., Griendling K.K. Modulation of vascular smooth muscle signaling by reactive oxygen species. Physiology, 2006; 21(4): 269-280. | |
| |
28. Panicker S.R., Sreenivas P., Babu M.S. et al. Quercetin attenuates Monocyte Chemoattractant Protein-1 gene expression in glucose primed aortic endothelial cells through NF-kappaB and AP-1. Pharmacol. Res, 2010; 62(4): 328-36. | |
| |
29. Perez-Vizcaino F., Ibarra M., Cogolludo A.L. et al. Endothelium-independent vasodilator effects of the flavonoid quercetin and its methylated metabolites in rat conductance and resistance arteries. J. Pharmacol. Exp. Ther, 2002; 302: 66-72. | |
| |
30. Sano T., Umeda F., Hashimoto T. et al. Oxidative stress measurement by in vivo electron spin resonance spectroscopy in rats with streptozotocin-induced diabetes. Diabetologia, 1998; 41: 1355-1360. | |
| |
31. Sarkar S., Mandal S., Sinha J.et al. Quercetin: critical evaluation as an antileishmanial agent in vivo in hamsters using different vesicular delivery modes. J. Drug Target, 2002; 10: 573-578. | |
| |
32. Schalkwijk C.G., Stehouwer C.D. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin. Sci. (Lond.), 2005; 109(2): 143-59. | |
| |
33. Soloviev A., Tishkin S., Kyrychenko S. Quercetin-filled phosphatidylcholine liposomes restore abnormalities in rat thoracic aorta BKCa channel function following ionizing irradiation. Acta Physiologica Sinica, 2009; 63(3): 201-210. | |
| |
34. Spitaler M.M., Graier W.F. Vascular targets of redox signalling in diabetes mellitus. Diabetologia, 2002; 45: 476-494. | |
| |
35. Suntres Z.E. Liposomal Antioxidants for Protection against Oxidant-Induced Damage. J. of Toxicol, 2011; P. 1-16. | |
| |
36. Taniyama Y., Griendling K.K. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension, 2003; 42:1075-1081. | |
| |
37. Tesfamariam B., Brown M.L., Deykin D., Cohen R.A. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J. Clin. Invest, 1990; 85(3): 929-932. | |
| |
38. The diabetes control and complications trial research group/epidemiology of diabetes interventions and complications research group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N. Eng. J. Med, 2000; 342: 381-389. | |
| |
39. Wang S., Xiong X., Song T., Liu L. Protective effects of cariporide on endothelial dysfunction induced by high glucose. Acta Pharmacologica Sinica, 2005; 26(3): 329-333. | |
| |
40. Wei M., Ong L., Smith M.T. et al. The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart Lung Circ, 2003; 12(1): 44-50. | |
| |
41. West I.C. Radicals and oxidative stress in diabetes. Diabet. Med, 2000; 17: 171-180. | |
| |
42. Wong W.T., Wong S.L., Tian X.Y., Huang Y. Endothelial dysfunction: the common consequence in diabetes and hypertension. J. Cardiovasc. Pharmacol, 2010; 55(4): 300-7. | |
| |
43. Yang G., Lucas R., Caldwell R., Yao L. et al. Novel mechanisms of endothelial dysfunction in diabetes. J. Cardiovasc. Dis. Res, 2010; 1(2): 59-63. | |
Refbacks
- There are currently no refbacks.
Copyright (c) 2013 Studia biologica
This work is licensed under a Creative Commons Attribution 4.0 International License.